Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

In several places they released that they would be marketing in the RUO and the market was $150 million. Then as noted in the intro on the AMBS page, someone twittered GC and he said no RUO revenue.

There is a reason for that research only means just that and not to be used in clinical trials, where it is used to make decisions on real patients.

That those TWO quotes remain on the AMBS is farcical. Since they were both released by AMBS, I left them there. They contradict each other, but well they speak to the quality of the management.

There is also this quote.

"However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value."

And does anyone really believe that with the incentive of a 30% increase in pay, the BODs is going to pause in their move to try and uplist?

Uplisting is for one purpose, to try and get funding. Folks seem oblivious to the massive dilution already in place, and the planned dilution if uplisting does not work and they need to draw on the LPC deal.

This company is just so much fun.